89bio, Inc (NASDAQ:ETNB) was plunging almost 10% lower on Friday in sympathy with the general market, which saw the S&P 500 plummeting over 2%.
In May, a number of analysts weighed in on 89bio following the biopharmaceutical company printing its first-quarter earnings on May 11. All four analysts are bullish on the stock.
